Tobacco smoking is associated with infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation

Hanajiri, Ryo; Kakihana, Kazuhiko; Kobayashi, Takeshi; Doki, Noriko; Sakamaki, Hisashi; Ohashi, Kazuteru

doi:10.1038/bmt.2015.116

Cited by 9 publications

(7 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, Hanajiri et al 5 did not find any association between smoking and OS or NRM among transplant recipients. In this study however, non-myeloablative transplants were also included in the analysis, which might have accounted for the observed difference.…”

mentioning

confidence: 89%

“…3,4 Despite the wellestablished health implications of cigarette smoking on various diseases including cancer, only a limited number of studies have evaluated its impact on outcome following allo-HSCT. [3][4][5][6] In addition, tobacco cigarettes contain fungal elements that could potentially lead to invasive fungal infections (IFIs), which are considered among the most dangerous complications of allo-HSCT. While smoking has been reported to be associated with infectious pulmonary complications, the association with IFI remains unclear.…”

mentioning

confidence: 99%

“…While smoking has been reported to be associated with infectious pulmonary complications, the association with IFI remains unclear. 5,7 We therefore evaluated the hypothesis that heavy cigarette smoking was associated with worse allo-HSCT outcomes, with a focus on IFI.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Impact of cigarette smoking on survival after myeloablative allogeneic hematopoietic stem cell transplantation and contribution of invasive fungal infection

Mehdi

Rybicki

Mossad

et al. 2017

Bone Marrow Transplant

View full text Add to dashboard Cite

mentioning

confidence: 89%

mentioning

confidence: 99%

See 1 more Smart Citation

Impact of cigarette smoking on survival after myeloablative allogeneic hematopoietic stem cell transplantation and contribution of invasive fungal infection

Mehdi

Rybicki

Mossad

et al. 2017

Bone Marrow Transplant

View full text Add to dashboard Cite

“…The medical histories of HM and HCT patients are among the most complex, representing unique disease chronologies, treatment courses/responses, and comorbidities. A history of tobacco smoking 10,27 and conditions such as chronic obstructive pulmonary disease predispose LRT colonization by bacterial pathogens, 28 thereby increasing the risk of infectious PCs. The development of mucositis, a common complication of myeloablative chemotherapies, may impair airway clearance and nutritional intake, thereby increasing the risk of pneumonia and bacteremic events.…”

Section: Risk Factorsmentioning

confidence: 99%

Diagnostic Evaluation of Pulmonary Abnormalities in Patients with Hematologic Malignancies and Hematopoietic Cell Transplantation

Harris

Geyer

2017

Clinics in Chest Medicine

View full text Add to dashboard Cite

Pulmonary complications (PC) of hematologic malignancies and their treatments are common causes of morbidity and mortality. Early diagnosis is challenging due to host risk factors, clinical instability, and provider preference. Delayed diagnosis impairs targeted treatment and may contribute to poor outcomes. An integrated understanding of clinical risk and radiographic patterns informs a timely approach to diagnosis and treatment. There is little prospective evidence guiding optimal modality and timing of minimally invasive lung sampling; however, a low threshold for diagnostic bronchoscopy during the first 24 to 72 hours after presentation should be a guiding principle in high-risk patients.

show abstract

“…Recently, tobacco smoking has been identified as a potential risk factor for respiratory infections after HSCT. 61 The type of HSCT (allogeneic vs autologous) and the presence of GVHD are also significant considerations in the spectrum of respiratory problems. Another consideration is that pulmonary complications after HSCT tend to follow a predictable timeline, as illustrated in Figure 1.…”

Section: Viral Pneumoniamentioning

confidence: 99%

Untitled

Diab

ZazaDitYafawi

Soubani³

2016

Exp Clin Transplant

View full text Add to dashboard Cite

Both autologous and allogeneic hematopoietic stem cell transplants are important therapeutic options for several benign and malignant disorders. Pulmonary complications, although they have become less frequent, remain a significant cause of morbidity and mortality after hematopoietic stem cell transplant. These complications range from bacterial, fungal, and viral pulmonary infections to noninfectious conditions such as diffuse alveolar hemorrhage and idiopathic pneumonia syndrome. Bronchiolitis obliterans syndrome is the primary chronic pulmonary complication, and treatment of this condition remains challenging. This report highlights the advances in the diagnosis and management of the major pulmonary complications after hematopoietic stem cell transplant. It also underscores the need for prospective and multicenter research to have a better understanding of the mechanisms behind these complications and to obtain more effective diagnostic tool and therapeutic options. Key words: Adverse effects, Lung diseases/etiology, Lung diseases/diagnosis, Respiratory tract infections/etiology, Graft versus host disease IntroductionHematopoietic stem cell transplant (HSCT) is increasingly being used for treatment of a wide range of benign and malignant diseases. About 50 000 to 60 000 HSCTs are done annually. 1 Hematopoietic stem cell transplant can be classified as autologous when the stem cells are harvested from the same patient and reinfused after high-dose chemotherapy, whereas, in allogeneic HSCT, the stem cells are donated by another person. Allogeneic HSCT can be related or unrelated and matched or mismatched. The hematopoietic stem cells might be derived from the bone marrow, umbilical cord, or peripheral blood.Hematopoietic stem cell transplant can be a lifesaving treatment of a wide range of neoplastic and nonneoplastic diseases; however, it is still limited by the development of serious complications. Advances in the preparative regimen using a nonmyeloablative preparative regimen, reduced-intensity conditioning transplants, and posttransplant supportive care have contributed to improved overall survival. Despite these advances, pulmonary complications still occur in about 37% of patient after HSCT 2 and are associated with significant morbidity and mortality. In 1 study, the hazard ratio for death due to pulmonary complications was 30. 1 However, there is evidence that the overall mortality and pulmonary complications after HSCT are improving. A recent review of allogeneic HSCT patients in a large transplant center from 1993 to 2007 showed that the risk of nonrelapse mortality decreased by 60% and overall mortality decreased by 41%. In addition, the risk of acute respiratory failure dropped by 36%, with risk of gram-negative bacterial and invasive mold infections decreasing by 39% and 51%. 3 In this study, we provide an update of the main pulmonary complications (both infectious and noninfectious) after HSCT, including an overview of the diagnostic approach and treatment of these complications. Noninfec...

show abstract

Tobacco smoking is associated with infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation

Cited by 9 publications

References 12 publications

Impact of cigarette smoking on survival after myeloablative allogeneic hematopoietic stem cell transplantation and contribution of invasive fungal infection

Impact of cigarette smoking on survival after myeloablative allogeneic hematopoietic stem cell transplantation and contribution of invasive fungal infection

Diagnostic Evaluation of Pulmonary Abnormalities in Patients with Hematologic Malignancies and Hematopoietic Cell Transplantation

Untitled

Contact Info

Product

Resources

About